3 active not recruiting, 3 completed, 3 recruiting, 1 not yet recruiting. 12 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 3, Completed 3, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 7 | Active not recruiting 3, Completed 2, Recruiting 1, Terminated 1 |
Follow AC220: new trials by email Literature Review of AC220 trials Research Report on AC220
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-11-02 |
| CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients Quizartinib, Etoposide, Dexrazoxane - Acute Myeloid Leukemia in Children | Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 60 | 2024-02-06 | 2025-08-05 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib - Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2020-05-27 | 2026-11-10 |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cladribine, Cytarabine, Idarubicin - Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2019-10-22 | 2026-06-12 |
| Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Quizartinib, Venetoclax - Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2019-01-25 | 2024-09-19 |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Decitabine, Quizartinib, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 129 | 2018-10-31 | 2026-11-03 |
| Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD Quizartinib, Omacetaxine Mepesuccinate Injection - AML, FLT3-ITD Mutation | Phase 2 | Unknown | The University of Hong Kong | 40 | 2017-10-01 | 2020-12-10 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 73 | 2013-11-12 | 2026-10-23 |
| Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia AC220 - Leukemia, Myeloid, Acute | Phase 2 | Completed | Daiichi Sankyo | 76 | 2012-04-01 | 2019-12-27 |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Plerixafor, AC220, Ganetespib - Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Cardiff University | 113 | 2011-04-01 | 2014-06-11 |
Leukemia, Myeloid, Acute (10) · Myelodysplastic Syndromes (5) · Leukemia, Myelomonocytic, Chronic (2) · Myeloproliferative Disorders (2) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Recurrence (1)
M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (2) · Cardiff University (1) · Daiichi Sankyo (1) · Princess Maxima Center for Pediatric Oncology (1) · The University of Hong Kong (1)
United States (8) · United Kingdom (2) · Canada (1) · France (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Puerto Rico (1)
Musa Yilmaz (3) · Alan K Burnett (1) · Anskar Leung, Professor (1) · Gertjan Kaspers, Prof. Dr. (1) · Guillermo M Bravo (1) · Jerald P Radich (1) · Keith W Pratz (1) · Michel Zwaan, Prof. Dr. (1) · Naval G Daver (1) · Nigel H Russell (1) · Yesid Alvarado, MD (1)
PMID 33208914, PMID 36902217, PMID 38744144, PMID 42321916
2023 (1), U10CA180820 (1), U10CA180888 (1)